U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172126) titled 'Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets' on Sept. 08.
Brief Summary: TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker. The phase I phase of this trial aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3201 tablets for the treatment of advanced prostate cancer.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-resistant Prostate Cancer
Intervention:
DRUG: TQB3...